Shielding thymus during lung cancer radiation may improve survival outcomes

For most of the twentieth century, doctors treated the thymus as a relic—an organ that mattered in childhood and then faded into irrelevance. The small gland behind the breastbone, responsible for training the immune system's T cells, was thought to shrink away to nothing by adulthood. But in the past few years, researchers at Mass General Brigham have upended that assumption. Two studies published in Nature showed that the adult thymus remains active and consequential throughout life, linked to longevity, heart health, cancer risk, and how well patients respond to modern immunotherapies. Now those same investigators have taken the logic one step further, with findings that could reshape how radiation oncologists treat lung cancer.

The question they asked was straightforward: if the thymus matters so much for immune function, what happens when it gets damaged by accident? During radiation therapy for lung cancer, the thymus often sits close enough to the tumor to receive substantial unintended exposure. No one was deliberately targeting it. But the collateral damage was real, and whether it mattered clinically had never been systematically studied at scale.

The research team analyzed CT scans and outcomes from more than one thousand patients with locally advanced non-small cell lung cancer. Using artificial intelligence to measure thymic health from routine imaging, they quantified how much radiation each patient's thymus received and tracked what happened afterward. The pattern that emerged was striking. Patients who started treatment with a healthy thymus and received lower incidental radiation doses to it had the best survival outcomes. But among those same patients—the ones with preserved thymic function before radiotherapy—those who received higher doses to the thymus experienced significantly worse overall survival and a substantially higher risk of cancer spreading to distant sites. Follow-up imaging confirmed the mechanism: patients who absorbed more thymic radiation showed measurable declines in thymic health.

The findings aligned with earlier work from the same group showing that patients with healthier thymuses got more benefit from immunotherapy drugs like durvalumab. In this study, that pattern held true. Patients receiving durvalumab who also had preserved thymic health seemed particularly vulnerable to the effects of thymic radiation—suggesting that the very patients most likely to benefit from immune-boosting drugs were the ones being harmed by incidental radiation damage to the immune system's training ground.

Hugo Aerts, director of the Artificial Intelligence in Medicine Program at Mass General Brigham and a co-senior author, framed the implications plainly: the adult thymus is far more important than medicine has traditionally appreciated, which naturally raises the question of whether it should be actively protected during cancer treatment. Raymond Mak, a radiation oncologist at the same institution, put it another way: successful cancer treatment is not only about destroying the tumor, but about preserving the patient's immune system. The patients who stand to gain the most from immunotherapy may also be the ones who gain the most from shielding the thymus during radiation.

The researchers are careful to note that this is observational research, not a controlled trial. Before thymus-sparing radiation techniques become standard practice, prospective clinical studies will be needed to confirm that actively protecting the thymus during treatment actually improves outcomes. But the findings provide the first large-scale clinical evidence that the thymus deserves consideration in radiation planning—that an organ long dismissed as irrelevant may hold the key to better survival for patients with one of the most common and deadly cancers.